From clinical uncertainties to precision medicine: the emerging role of the gut barrier and microbiome in small bowel functional diseases

References

• Da D. Functional gastrointestinal disorders: history, pathophysiology, clinical features and Rome IV. Gastroenterology. 2016;pii:S0016-5085(16)00223-7.
   Google Scholar
• Koppen IJ, Nurko S, Saps M, et al. The pediatric Rome IV criteria: what’s new? Expert Rev Gastroenterol Hepatol. 2017;11:193–201.
   PubMed Web of Science ®Google Scholar
• Otani K, Tanigawa T, Watanabe T, et al. Microbiota plays a key role in non-steroidal anti-inflammatory drug-induced small intestinal damage. Digestion. 2017;95:22–28.
   PubMed Web of Science ®Google Scholar
• Syer SD, Blackler RW, Martin R, et al. NSAID enteropathy and bacteria: a complicated relationship. J Gastroenterol. 2015;50:387–393.
   PubMed Web of Science ®Google Scholar
• Marlicz W, Loniewski I, Grimes DS, et al. Nonsteroidal anti-inflammatory drugs, proton pump inhibitors, and gastrointestinal injury: contrasting interactions in the stomach and small intestine. Mayo Clin Proc. 2014;89:1699–1709.
   PubMed Web of Science ®Google Scholar
• Shepard R. Greys anatomy. London (UK): Stanhope Books; 2014.
   Google Scholar
• Sobotta J, Figge FHJ, Hild WJ. Atlas of human anatomy. New York, NY: Hefner; 1974.
   Google Scholar
• Volk N, Lacy B. Anatomy and physiology of the small bowel. Gastrointest Endosc Clin N Am. 2017;27:1–13.
   PubMedGoogle Scholar
• Potten C, Gandara R, Mahida YR, et al. The stem cells of small intestinal crypts: where are they? Cell Prolif. 2009;42:731–750.
   PubMed Web of Science ®Google Scholar
• Odenwald MA, Turner JR. The intestinal epithelial barrier: a therapeutic target? Nat Rev Gastroenterol Hepatol. 2017;14:9–21.
   PubMed Web of Science ®Google Scholar
• Lee SH. Intestinal permeability regulation by tight junction: implication on inflammatory bowel diseases. Intest Res. 2015;13:11–18.
   PubMed Web of Science ®Google Scholar
• Spadoni I, Zagato E, Bertocchi A, et al. A gut-vascular barrier controls the systemic dissemination of bacteria. Science. 2015;350:830–834.
   PubMed Web of Science ®Google Scholar
• König J, Wells J, Cani PD, et al. Human intestinal barrier function in health and disease. Clin Transl Gastroenterol. 2016;7:e196.
   PubMed Web of Science ®Google Scholar
• Cohen CJ, Shieh JT, Pickles RJ, et al. The coxsackievirus and adenovirus receptor is a transmembrane component of the tight junction. Proc Natl Acad Sci U S A. 2001;98:15191–15196.
   PubMed Web of Science ®Google Scholar
• Latorre IJ, Roh MH, Frese KK, et al. Viral oncoprotein-induced mislocalization of select PDZ proteins disrupts tight junctions and causes polarity defects in epithelial cells. J Cell Sci. 2005;118:4283–4293.
   PubMed Web of Science ®Google Scholar
• Ellencrona K, Syed A, Johansson M. Flavivirus NS5 associates with host-cell proteins zonula occludens-1 (ZO-1) and regulating synaptic membrane exocytosis-2 (RIMS2) via an internal PDZ binding mechanism. Biol Chem. 2009;390:319–323.
   PubMed Web of Science ®Google Scholar
• Liu S, Yang W, Shen L, et al. Tight junction proteins claudin-1 and occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfection. J Virol. 2009;83:2011–2014.
   PubMed Web of Science ®Google Scholar
• Ploss A, Evans MJ, Gaysinskaya VA, et al. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature. 2009;457:882–886.
   PubMed Web of Science ®Google Scholar
• Meertens L, Bertaux C, Cukierman L, et al. The tight junction proteins claudin-1, −6, and −9 are entry cofactors for hepatitis C virus. J Virol. 2008;82:3555–3560.
   PubMed Web of Science ®Google Scholar
• Kaushic C. HIV-1 infection in the female reproductive tract: role of interactions between HIV-1 and genital epithelial cells. Am J Reprod Immunol. 2011;65:253–260.
   PubMed Web of Science ®Google Scholar
• Nazli A, Chan O, Dobson-Belaire WN, et al. Exposure to HIV-1 directly impairs mucosal epithelial barrier integrity allowing microbial translocation. Plos Pathol. 2010;6:e1000852.
   PubMed Web of Science ®Google Scholar
• Zheng J, Xie Y, Campbell R, et al. Involvement of claudin-7 in HIV infection of CD4(-) cells. Retrovirology. 2005;2:79.
   PubMed Web of Science ®Google Scholar
• Barton ES, Forrest JC, Connolly JL, et al. Junction adhesion molecule is a receptor for reovirus. Cell. 2001;104:441–451.
   PubMed Web of Science ®Google Scholar
• Berkova Z, Crawford SE, Blutt SE, et al. Expression of rotavirus NSP4 alters the actin network organization through the actin remodeling protein cofilin. J Virol. 2007;81:3545–3553.
   PubMed Web of Science ®Google Scholar
• Masaki T, Kojima T, Okabayashi T, et al. A nuclear factor-κB signaling pathway via protein kinase C δ regulates replication of respiratory syncytial virus in polarized normal human nasal epithelial cells. Mol Biol Cell. 2011;22:2144–2156.
   PubMed Web of Science ®Google Scholar
• Teoh KT, Siu YL, Chan WL, et al. The SARS coronavirus E protein interacts with PALS1 and alters tight junction formation and epithelial morphogenesis. Mol Biol Cell. 2010;21:3838–3852.
   PubMed Web of Science ®Google Scholar
• Veshnyakova A, Protze J, Rossa J, et al. On the interaction of Clostridium perfringens enterotoxin with claudins. Toxins (Basel). 2010;2:1336–1356.
   PubMed Web of Science ®Google Scholar
• Mitchell LA, Koval M. Specificity of interaction between clostridium perfringens enterotoxin and claudin-family tight junction proteins. Toxins (Basel). 2010;2:1595–1611.
   PubMed Web of Science ®Google Scholar
• Sonoda N, Furuse M, Sasaki H, et al. Clostridium perfringens enterotoxin fragment removes specific claudins from tight junction strands. Evidence for direct involvement of claudins in tight junction barrier. J Cell Biol. 1999;147:195–204.
   PubMed Web of Science ®Google Scholar
• Strauman MC, Harper JM, Harrington SM, et al. Enteroaggregative Escherichia coli disrupts epithelial cell tight junctions. Infect Immun. 2010;78:4958–4964.
   PubMed Web of Science ®Google Scholar
• Roxas JL, Koutsouris A, Bellmeyer A, et al. Enterohemorrhagic E. coli alters murine intestinal epithelial tight junction protein expression and barrier function in a Shiga toxin independent manner. Lab Invest. 2010;90:1152–1168.
   PubMed Web of Science ®Google Scholar
• Mankertz J, Amasheh M, Krug SM, et al. TNFalpha up-regulates claudin-2 expression in epithelial HT-29/B6 cells via phosphatidylinositol-3-kinase signaling. Cell Tissue Res. 2009;336:67–77.
   PubMed Web of Science ®Google Scholar
• Howe KL, Reardon C, Wang A, et al. Transforming growth factor-beta regulation of epithelial tight junction proteins enhances barrier function and blocks enterohemorrhagic Escherichia coli O157, H7-induced increased permeability. Am J Pathol. 2005;167:1587–1597.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Li Q, Wang C, et al. Redistribution of tight junction proteins during EPEC infection in vivo. Inflammation. 2012;35:23–32.
   PubMed Web of Science ®Google Scholar
• Sason H, Milgrom M, Weiss AM, et al. Enteropathogenic Escherichia coli subverts phosphatidylinositol 4,5-bisphosphate and phosphatidylinositol 3,4,5-trisphosphate upon epithelial cell infection. Mol Biol Cell. 2009;20:544–555.
   PubMed Web of Science ®Google Scholar
• Czeczulin JR, Hanna PC, McClane BA. Cloning, nucleotide sequencing, and expression of the Clostridium perfringens enterotoxin gene in Escherichia coli. Infect Immun. 1993;61:3429–3439.
   PubMed Web of Science ®Google Scholar
• Saadat I, Higashi H, Obuse C, et al. Helicobacter pylori CagA targets PAR1/MARK kinase to disrupt epithelial cell polarity. Nature. 2007;447:330–333.
   PubMed Web of Science ®Google Scholar
• Amieva MR, Vogelmann R, Covacci A, et al. Disruption of the epithelial apical-junctional complex by Helicobacter pylori CagA. Science. 2003;300:1430–1434.
   PubMed Web of Science ®Google Scholar
• Hanajima-Ozawa M, Matsuzawa T, Fukui A, et al. Enteropathogenic Escherichia coli, Shigella flexneri, and Listeria monocytogenes recruit a junctional protein, zonula occludens-1, to actin tails and pedestals. Infect Immun. 2007;75:565–573.
   PubMed Web of Science ®Google Scholar
• Köhler H, Sakaguchi T, Hurley BP, et al. Salmonella enterica serovar Typhimurium regulates intercellular junction proteins and facilitates transepithelial neutrophil and bacterial passage. Am J Physiol Gastrointest Liver Physiol. 2007;293:G178–87.
   PubMed Web of Science ®Google Scholar
• Fukumatsu M, Ogawa M, Arakawa S, et al. Shigella targets epithelial tricellular junctions and uses a noncanonical clathrin-dependent endocytic pathway to spread between cell. Cell Host Microbe. 2012;11:325–336.
   PubMed Web of Science ®Google Scholar
• Sakaguchi T, Köhler H, Gu X, et al. Shigella flexneri regulates tight junction-associated proteins in human intestinal epithelial cells. Cell Microbiol. 2002;4:367–381.
   PubMed Web of Science ®Google Scholar
• Wu Z, Nybom P, Magnusson KE. Distinct effects of Vibrio cholerae haemagglutinin/protease on the structure and localization of the tight junction-associated proteins occludin and ZO-1. Cell Microbiol. 2000;2:11–17.
   PubMed Web of Science ®Google Scholar
• Foch NR. Netter’s gastroenterology. Philadelphia, NY: Elsevier Saunders; 2005.
   Google Scholar
• Salvo-Romero E, Alonso-Cotoner C, Pardo-Camacho C, et al. The intestinal barrier function and its involvement in digestive disease. Rev Esp Enferm Dig. 2015;107:686–696.
   PubMed Web of Science ®Google Scholar
• Jónsdóttir I. Maturation of mucosal immune responses and influence of maternal antibodies. J Comp.Path. 2007;37:S20–S26.
   Web of Science ®Google Scholar
• Leser TD, Mølbak L. Better living through microbial action: the benefits of the mammalian gastrointestinal microbiota on the host. Environ Microbiol. 2009;11:2194–2206.
   PubMed Web of Science ®Google Scholar
• Cotter PD. Small intestine and microbiota. Curr Opin Gastroenterol. 2011;27:99–105.
   PubMed Web of Science ®Google Scholar
• Booijink CC, El-Aidy S, Rajilic-Stojanovic M, et al. High temporal and inter-individual variation detected in the human ileal microbiota. Environ Microbiol. 2010;12:3213–3227.
   PubMed Web of Science ®Google Scholar
• Oh PL, Martínez I, Sun Y, et al. Characterization of the ileal microbiota in rejecting and nonrejecting recipients of small bowel transplants. Am J Transplant. 2012;12:753–762.
   PubMed Web of Science ®Google Scholar
• Zoetendal EG, Raes J, van den Bogert B, et al. The human small intestinal microbiota is driven by rapid uptake and conversion of simple carbohydrates. Isme J. 2012;6:1415–1426.
   PubMed Web of Science ®Google Scholar
• Hartman AL, Lough DM, Barupal DK, et al. Human gut microbiome adopts an alternative state following small bowel transplantation. Proc Natl Acad Sci U S A. 2009;106:17187–17192.
   PubMed Web of Science ®Google Scholar
• El Aidy S, van den Bogert B, Kleerebezem M. The small intestine microbiota, nutritional modulation and relevance for health. Curr Opin Biotechnol. 2015;32:14–20.
   PubMed Web of Science ®Google Scholar
• Morikawa M, Tsujibe S, Kiyoshima-Shibata J, et al. Microbiota of the small intestine is selectively engulfed by phagocytes of the lamina propria and Peyer’s patches. Plos One. 2016;11:e0163607.
   PubMed Web of Science ®Google Scholar
• van den Bogert B, Meijerink M, Zoetendal EG, et al. Immunomodulatory properties of Streptococcus and Veillonella isolates from the human small intestine microbiota. Plos One. 2014;9:e114277.
   PubMed Web of Science ®Google Scholar
• van Baarlen P, Troost F, van der Meer C, et al. Human mucosal in vivo transcriptome responses to three lactobacilli indicate how probiotics may modulate human cellular pathways. Proc Natl Acad Sci U S A. 2011;108(Suppl 1):4562–4569.
   PubMed Web of Science ®Google Scholar
• van Baarlen P, Troost FJ, van Hemert S, et al. Differential NF-kappaB pathways induction by Lactobacillus plantarum in the duodenum of healthy humans correlating with immune tolerance. Proc Natl Acad Sci U S A. 2009;106:2371–2376.
   PubMed Web of Science ®Google Scholar
• Zhong L, Shanahan ER, Raj A, et al. Dyspepsia and the microbiome: time to focus on the small intestine. Gut. 2016;pii:gutjnl-2016-312574.
   Google Scholar
• Giamarellos-Bourboulis E, Tang J, Pyleris E, et al. Molecular assessment of differences in the duodenal microbiome in subjects with irritable bowel syndrome. Scand J Gastroenterol. 2015;50:1076–1087.
   PubMed Web of Science ®Google Scholar
• Shen L, Weber CR, Raleigh DR, et al. Tight junction pore and leak pathways: a dynamic duo. Annu Rev Physiol. 2011;73:283–309.
   PubMed Web of Science ®Google Scholar
• Kiesler P, Fuss IJ, Strober W. Experimental models of inflammatory bowel diseases. Cell Mol Gastroenterol Hepatol. 2015;1:154–170.
   PubMed Web of Science ®Google Scholar
• Weber CR, Raleigh DR, Su L, et al. Epithelial myosin light chain kinase activation induces mucosal interleukin-13 expression to alter tight junction ion selectivity. J Biol Chem. 2010;285:12037–12046.
   PubMed Web of Science ®Google Scholar
• Suenaert P, Bulteel V, Lemmens L, et al. Anti-tumor necrosis factor treatment restores the gut barrier in Crohn’s disease. Am J Gastroenterol. 2002;97:2000–2004.
   PubMed Web of Science ®Google Scholar
• Clayburgh DR, Barrett TA, Tang Y, et al. Epithelial myosin light chain kinase-dependent barrier dysfunction mediates T cell activation-induced diarrhea in vivo. J Clin Invest. 2005;115:2702–2715.
   PubMed Web of Science ®Google Scholar
• Graham WV, Wang F, Clayburgh DR, et al. Tumor necrosis factor-induced long myosin light chain kinase transcription is regulated by differentiation-dependent signaling events. Characterization of the human long myosin light chain kinase promoter. J Biol Chem. 2006;281:26205–26215.
   PubMed Web of Science ®Google Scholar
• Marchiando AM, Shen L, Graham WV, et al. Caveolin-1-dependent occludin endocytosis is required for TNF-induced tight junction regulation in vivo. J Cell Biol. 2010;189:111–126.
   PubMed Web of Science ®Google Scholar
• Westphal JK, Dörfel MJ, Krug SM, et al. Tricellulin forms homomeric and heteromeric tight junctional complexes. Cell Mol Life Sci. 2010;67:2057–2068.
   PubMed Web of Science ®Google Scholar
• Ikenouchi J, Sasaki H, Tsukita S, et al. Loss of occludin affects tricellular localization of tricellulin. Mol Biol Cell. 2008;19:4687–4693.
   PubMed Web of Science ®Google Scholar
• Villani AC, Lemire M, Thabane M, et al. Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. Gastroenterology. 2010;138:1502–1513.
   PubMed Web of Science ®Google Scholar
• Sheaffer KL, Kim R, Aoki R, et al. DNA methylation is required for the control of stem cell differentiation in the small intestine. Genes Dev. 2014;28:652–664.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Costinean S, Croce CM, et al. MicroRNA 29 targets nuclear factor-κB-repressing factor and Claudin 1 to increase intestinal permeability. Gastroenterology. 2015;148:158–169.e8.
   PubMed Web of Science ®Google Scholar
• Kasubuchi M, Hasegawa S, Hiramatsu T, et al. Dietary gut microbial metabolites, short-chain fatty acids, and host metabolic regulation. Nutrients. 2015;7:2839–2849.
   PubMed Web of Science ®Google Scholar
• Lozupone CA, Stombaugh JI, Gordon JI, et al. Diversity, stability and resilience of the human gut microbiota. Nature. 2012;489:220–230.
   PubMed Web of Science ®Google Scholar
• EL Aidy S, Derrien M, Aardema R, et al. Transient inflammatory-like state and microbial dysbiosis are pivotal in establishment of mucosal homeostasis during colonisation of germ-free mice. Benef Microbes. 2014;5:67–77.
   PubMed Web of Science ®Google Scholar
• Rescigno M, Di Sabatino A. Dendritic cells in intestinal homeostasis and disease. J Clin Invest. 2009;119:2441–2450.
   PubMed Web of Science ®Google Scholar
• Corthésy B. Multi-faceted functions of secretory IgA at mucosal surfaces. Front Immunol. 2013;4:185.
   PubMed Web of Science ®Google Scholar
• Takatori H, Kanno Y, Watford WT, et al. Lymphoid tissue inducer-like cells are an innate source of IL-17 and IL-22. J Exp Med. 2009;206:35–41.
   PubMed Web of Science ®Google Scholar
• Lee YK, Mazmanian SK. Microbial learning lessons: SFB educate the immune system. Immunity. 2014;40:457–459.
   PubMed Web of Science ®Google Scholar
• Bischoff SC, Barbara G, Buurman W, et al. Intestinal permeability–a new target for disease prevention and therapy. BMC Gastroenterol. 2014;14:189.
   PubMed Web of Science ®Google Scholar
• DeMeo MT, Mutlu EA, Keshavarzian A, et al. Intestinal permeation and gastrointestinal disease. J Clin Gastroenterol. 2002;34:385–396.
   PubMed Web of Science ®Google Scholar
• Anderson AD, Jain PK, Fleming S, et al. Evaluation of a triple sugar test of colonic permeability in humans. Acta Physiol Scand. 2004;182:171–177.
   PubMedGoogle Scholar
• van Wijck K, Verlinden TJ, van Eijk HM, et al. Novel multi-sugar assay for site-specific gastrointestinal permeability analysis: a randomized controlled crossover trial. Clin Nutr. 2013;32:245–251.
   PubMed Web of Science ®Google Scholar
• Mankertz J, Schulzke JD. Altered permeability in inflammatory bowel disease: pathophysiology and clinical implications. Curr Opin Gastroenterol. 2007;23:379–383.
   PubMed Web of Science ®Google Scholar
• Smecuol E, Bai JC, Vazquez H, et al. Gastrointestinal permeability in celiac disease. Gastroenterology. 1997;112:1129–1136.
   PubMed Web of Science ®Google Scholar
• Troncone R, Caputo N, Florio G, et al. Increased intestinal sugar permeability after challenge in children with cow’s milk allergy or intolerance. Allergy. 1994;49:142–146.
   PubMed Web of Science ®Google Scholar
• Ventura MT, Polimeno L, Amoruso AC, et al. Intestinal permeability in patients with adverse reactions to food. Dig Liver Dis. 2006;38:732–736.
   PubMedGoogle Scholar
• Kerckhoffs AP, Akkermans LM, de Smet MB, et al. Intestinal permeability in irritable bowel syndrome patients: effects of NSAIDs. Dig Dis Sci. 2010;55:716–723.
   PubMed Web of Science ®Google Scholar
• Ammori BJ, Leeder PC, King RF, et al. Early increase in intestinal permeability in patients with severe acute pancreatitis: correlation with endotoxemia, organ failure, and mortality. J Gastrointest Surg. 1999;3:252–262.
   PubMed Web of Science ®Google Scholar
• Solligård E, Juel IS, Spigset O, et al. Gut luminal lactate measured by microdialysis mirrors permeability of the intestinal mucosa after ischemia. Shock. 2008;9:245–251.
   Google Scholar
• Grootjans J, Thuijls G, Verdam F, et al. Noninvasive assessment of barrier integrity and function of the human gut. World J Gastrointest Surg. 2010;2:61–69.
   PubMedGoogle Scholar
• Bergheim I, Weber S, Vos M, et al. Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin. J Hepatol. 2008;48:983–992.
   PubMed Web of Science ®Google Scholar
• Pendyala S, Walker JM, Holt PR. A high-fat diet is associated with endotoxemia that originates from the gut. Gastroenterology. 2012;142:1100–1111.
   PubMed Web of Science ®Google Scholar
• Dlugosz A, Nowak P, D’Amato M, et al. Increased serum levels of lipopolysaccharide and antiflagellin antibodies in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil. 2015;27:1747–1754.
   PubMed Web of Science ®Google Scholar
• Strutz F, Heller G, Krasemann K, et al. Relationship of antibodies to endotoxin core to mortality in medical patients with sepsis syndrome. Intensive Care Med. 1999;25:435–444.
   PubMed Web of Science ®Google Scholar
• Bates DW, Parsonnet J, Ketchum PA, et al. Limulus amebocyte lysate assay for detection of endotoxin in patients with sepsis syndrome, AMCC Sepsis Project Working Group. Clin Infect Dis. 1998;27:582–591.
   PubMed Web of Science ®Google Scholar
• Johansson ME, Gustafsson JK, Holmén-Larsson J, et al. Bacteria penetrate the normally impenetrable inner colon mucus layer in both murine colitis models and patients with ulcerative colitis. Gut. 2014;63:281–291.
   PubMed Web of Science ®Google Scholar
• Crenn P, Vahedi K, Lavergne-Slove A, et al. Plasma citrulline: a marker of enterocyte mass in villous atrophy-associated small bowel disease. Gastroenterology. 2003;124:1210–1219.
   PubMed Web of Science ®Google Scholar
• Crenn P, Coudray-Lucas C, Thuillier F, et al. Postabsorptive plasma citrulline concentration is a marker of absorptive enterocyte mass and intestinal failure in humans. Gastroenterology. 2000;119:1496–1505.
   PubMed Web of Science ®Google Scholar
• Reisinger KW, Derikx JP, Thuijls G, et al. Noninvasive measurement of intestinal epithelial damage at time of refeeding can predict clinical outcome after necrotizing enterocolitis. Pediatr Res. 2012;73:209–213.
   PubMed Web of Science ®Google Scholar
• Adriaanse MP, Tack GJ, Passos VL, et al. Serum I-FABP as marker for enterocyte damage in coeliac disease and its relation to villous atrophy and circulating autoantibodies. Aliment Pharmacol Ther. 2013;37:482–490.
   PubMed Web of Science ®Google Scholar
• Gearhart SL, Delaney CP, Senagore AJ, et al. Prospective assessment of the predictive value of alphaglutathione S-transferase for intestinal ischemia. Am Surg. 2003;69:324–329.
   PubMed Web of Science ®Google Scholar
• Fagerhol MK. Calprotectin: a faecal marker of organic gastrointestinal abnormality. Lancet. 2000;356:1783–1784.
   PubMed Web of Science ®Google Scholar
• Bunn SK, Bisset WM, Main MJ, et al. Fecal calprotectin: validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease. J Pediatr Gastroentreol Nutr. 2001;33:14–22.
   PubMed Web of Science ®Google Scholar
• Von Arnim U, Wex T, Ganzert C, et al. Fecal calprotectin: a marker for clinical differentiation of microscopic colitis and irritable bowel syndrome. Clin Exp Gastroenterol. 2016;9:97–103.
   PubMed Web of Science ®Google Scholar
• Boyapati RK, Kalla R, Satsangi J, et al. Biomarkers in search of precision medicine in IBD. Am J Gastroenterol. 2016;111:1682–1690.
   PubMed Web of Science ®Google Scholar
• Kalla R, Kennedy NA, Ventham NT, et al. Serum calprotectin: a novel diagnostic and prognostic marker in inflammatory bowel diseases. Am J Gastroenterol. 2016;111:1796–1805.
   PubMed Web of Science ®Google Scholar
• van den Bogert B, Erkus O, Boekhorst J, et al. Diversity of human small intestinal Streptococcus and Veillonella populations. FEMS Microbiol Ecol. 2013;85:376–388.
   PubMed Web of Science ®Google Scholar
• van der Schaar PJ, Dijksman JF, Broekhuizen-De Gast H, et al. A novel ingestible electronic drug delivery and monitoring device. Gastrointest Endosc. 2013;78:520–528.
   PubMed Web of Science ®Google Scholar
• Malagelada C, Drozdzal M, Seguí S, et al. Classification of functional bowel disorders by objective physiological criteria based on endoluminal image analysis. Am J Physiol Gastrointest Liver Physiol. 2015;309::G413-9.
   PubMed Web of Science ®Google Scholar
• Malagelada C, De Iorio F, Azpiroz F, et al. New insight into intestinal motor function via noninvasive endoluminal image analysis. Gastroenterology. 2008;135:1155–1162.
   PubMed Web of Science ®Google Scholar
• Nakamura M, Niwa Y, Yagihashi M, et al. New objective evaluation method for functional bowel disorder using video capsule endoscopy. Dig Endosc. 2009;21:29–33.
   PubMed Web of Science ®Google Scholar
• Nakamura M, Ohmiya N, Miyahara R, et al. Are symptomatic changes in irritable bowel syndrome correlated with the capsule endoscopy transit time? A pilot study using the 5-HT4 receptor agonist mosapride. Hepatogastroenterology. 2011;58:453–458.
   PubMedGoogle Scholar
• Kalla R, McAlindon ME, Sanders DS, et al. Subtle mucosal changes at capsule endoscopy in diarrhoea predominant irritable bowel syndrome. Med Hypotheses. 2012;79:423.
   PubMed Web of Science ®Google Scholar
• Ohlsson B, Bengtsson M, Nielsen J, et al. A prospective evaluation of the diagnostic value of video capsule endoscopy in patients initially classified as irritable bowel syndrome. Eur J Intern Med. 2009;20:48–52.
   PubMed Web of Science ®Google Scholar
• Saad RJ. The wireless motility capsule: a one-stop shop for the evaluation of GI motility disorders. Curr Gastroenterol Rep. 2016;18:14.
   PubMedGoogle Scholar
• Tran K, Brun R, Kuo B. Evaluation of regional and whole gut motility using the wireless motility capsule: relevance in clinical practice. Therap Adv Gastroenterol. 2012;5:249–260.
   PubMed Web of Science ®Google Scholar
• Roland BC, Ciarleglio MM, Clarke JO, et al. Small intestinal transit time is delayed in small intestinal bacterial overgrowth. J Clin Gastroenterol. 2015;49:571–576.
   PubMed Web of Science ®Google Scholar
• DuPont AW, Jiang ZD, Harold SA, et al. Motility abnormalities in irritable bowel syndrome. Digestion. 2014;89:119–123.
   PubMed Web of Science ®Google Scholar
• Ringel-Kulka T, Choi CH, Temas D, et al. Altered colonic bacterial fermentation as a potential pathophysiological factor in irritable bowel syndrome. Am J Gastroenterol. 2015;110:1339–1346.
   PubMed Web of Science ®Google Scholar
• Yung D, Douglas S, Hobson AR, et al. Morpho-functional evaluation of small bowel using wireless motility capsule and video capsule endoscopy in patients with known or suspected Crohn’s disease: pilot study. Endosc Int Open. 2016;4:E480–6.
   PubMed Web of Science ®Google Scholar
• Dinning PG, Scott SM. Novel diagnostics and therapy of colonic motor disorders. Curr Opin Pharmacol. 2011;11:624–629.
   PubMed Web of Science ®Google Scholar
• Andersen K, Haase A, Agnholt J, et al. Gastrointestinal transit times and abdominal pain in Crohn’s disease. Inflamm Bowel Dis. 2017;27:113.
   Google Scholar
• Fynne L, Worsøe J, Gregersen T, et al. Gastrointestinal transit in patients with systemic sclerosis. Scand J Gastroenterol. 2011;46:1187–1193.
   PubMed Web of Science ®Google Scholar
• Karlsen S, Fynne L, Grønbæk H, et al. Small intestinal transit in patients with liver cirrhosis and portal hypertension: a descriptive study. BMC Gastroenterol. 2012;12:176.
   PubMed Web of Science ®Google Scholar
• Turcotte JF, Kao D, Mah SJ, et al. Breaks in the wall: increased gaps in the intestinal epithelium of irritable bowel syndrome patients identified by confocal laser endomicroscopy (with videos). Gastrointest Endosc. 2013;77:624–630.
   PubMed Web of Science ®Google Scholar
• Hosoe N, Ogata H. Application and efficacy of super-magnifying endoscopy for the lower intestinal tract. Clin Endosc. 2016;49:37–40.
   PubMedGoogle Scholar
• Zaidi D, Bording-Jorgensen M, Huynh HQ, et al. Increased epithelial gap density in the noninflamed duodenum of children with inflammatory bowel diseases. J Pediatr Gastroenterol Nutr. 2016;63(6):644–650.
   PubMed Web of Science ®Google Scholar
• Hosoe N, Ogata H, Hibi T. Endoscopic imaging of parasites in the human digestive tract. Parasitol Int. 2014;63:216–220.
   PubMed Web of Science ®Google Scholar
• Talley NJ. Editorial: moving away from focussing on gastric pathophysiology in functional dyspepsia, new insights and therapeutic implications. Am J Gastroenterol. 2017;112:141–144.
   PubMed Web of Science ®Google Scholar
• Sugano K, Tack J, Kuipers EJ, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64:1353–1367.
   Google Scholar
• Tan VP, Liu KS, Lam FY, et al. Randomised clinical trial: rifaximin versus placebo for the treatment of functional dyspepsia. Aliment Pharmacol Ther. 2017;45:767–776.
   PubMed Web of Science ®Google Scholar
• Mujagic Z, de Vos P, Boekschoten MV, et al. The effects of Lactobacillus plantarum on small intestinal barrier function and mucosal gene transcription: a randomized double-blind placebo controlled trial. Sci Rep. 2017;7:40128.
   PubMed Web of Science ®Google Scholar
• Miazga A, Osinski M, Cichy W, et al. Current views on the etiopathogenesis, clinical manifestation, diagnostics, treatment and correlation with other nosological entities of SIBO. Adv Med Sci. 2015;60:118–124.
   PubMed Web of Science ®Google Scholar
• Dukowicz AC, Lacy BE, Levine GM. Small intestinal bacterial overgrowth: a comprehensive review. Gastroenterol Hepatol (NY). 2007;3:112–122.
   PubMedGoogle Scholar
• Sachdev AH, Pimentel M. Gastrointestinal bacterial overgrowth, pathogenesis and clinical significance. Ther Adv Chronic Dis. 2013;4:223–231.
   PubMedGoogle Scholar
• Krajicek EJ, Hansel SL. Small intestinal bacterial overgrowth: a primary care review. Mayo Clin Proc. 2016;91:1828–1833.
   PubMed Web of Science ®Google Scholar
• Grace E, Shaw C, Whelan K, et al. Review article: small intestinal bacterial overgrowth – prevalence, clinical features, current and developing diagnostic tests, and treatment. Aliment Pharmacol Ther. 2013;38:674–688.
   PubMed Web of Science ®Google Scholar
• Jacobs C, Coss Adame E, Attaluri A, et al. Dysmotility and proton pump inhibitor use are independent risk factors for small intestinal bacterial and/or fungal overgrowth. Aliment Pharmacol Ther. 2013;37:1103–1111.
   PubMed Web of Science ®Google Scholar
• Levitt MD, Bond JH Jr. Volume, composition, and source of intestinal gas. Gastroenterology. 1970;59:921–929.
   PubMed Web of Science ®Google Scholar
• Quigley EM. Small intestinal bacterial overgrowth: what it is and what it is not. Curr Opin Gastroenterol. 2014;30:141–146.
   PubMed Web of Science ®Google Scholar
• Sellin JH. A breath of fresh air. Clin Gastroenterol Hepatol. 2016;14:209–211.
   PubMed Web of Science ®Google Scholar
• Shah SC, Day LW, Somsouk M, et al. Meta-analysis: antibiotic therapy for small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2013;38:925–934.
   PubMed Web of Science ®Google Scholar
• Pimentel M, Wallace D, Hallegua D, et al. A link between irritable bowel syndrome and fibromyalgia may be related to findings on lactulose breath testing. Ann Rheum Dis. 2004;63:450–452.
   PubMed Web of Science ®Google Scholar
• Martínez C, Lobo B, Pigrau M, et al. Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier. Gut. 2013;62:1160–1168.
   PubMed Web of Science ®Google Scholar
• Martínez C, Vicario M, Ramos L, et al. The jejunum of diarrhea-predominant irritable bowel syndrome shows molecular alterations in the tight junction signaling pathway that are associated with mucosal pathobiology and clinical manifestations. Am J Gastroenterol. 2012;107:736–746.
   PubMed Web of Science ®Google Scholar
• Kong WM, Gong J, Dong L, et al. Changes of tight junction claudin-1,-3,-4 protein expression in the intestinal mucosa in patients with irritable bowel syndrome. Nan Fang Yi Ke Da Xue Xue Bao. 2007;27:1345–1347. Abstract
   PubMedGoogle Scholar
• Wittkopf N, Neurath MF, Becker C. Immune-epithelial crosstalk at the intestinal surface. J Gastroenterol. 2014;49:375–387.
   PubMed Web of Science ®Google Scholar
• Walker MM, Talley NJ, Prabhakar M, et al. Duodenal mastocytosis, eosinophilia and intraepithelial lymphocytosis as possible disease markers in the irritable bowel syndrome and functional dyspepsia. Aliment Pharmacol Ther. 2009;29:765–773.
   PubMed Web of Science ®Google Scholar
• Vicario M, González-Castro AM, Martínez C, et al. Increased humoral immunity in the jejunum of diarrhoea-predominant irritable bowel syndrome associated with clinical manifestations. Gut. 2015;64:1379–1388.
   PubMed Web of Science ®Google Scholar
• Wang SH, Dong L, Luo JY, et al. Decreased expression of serotonin in the jejunum and increased numbers of mast cells in the terminal ileum in patients with irritable bowel syndrome. World J Gastroenterol. 2007;13:6041–6047.
   PubMed Web of Science ®Google Scholar
• Park JH, Rhee PL, Kim HS, et al. Mucosal mast cell counts correlate with visceral hypersensitivity in patients with diarrhea predominant irritable bowel syndrome. J Gastroenterol Hepatol. 2006;21:71–78.
   PubMed Web of Science ®Google Scholar
• Barbara G, Wang B, Stanghellini V, et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology. 2007;132:26–37.
   PubMed Web of Science ®Google Scholar
• Guilarte M, Santos J, De Torres I, et al. Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut. 2007;56:203–209.
   PubMed Web of Science ®Google Scholar
• Vanheel H, Vicario M, Vanuytsel T, et al. Impaired duodenal mucosal integrity and low-grade inflammation in functional dyspepsia. Gut. 2014;63:262–271.
   PubMed Web of Science ®Google Scholar
• Wang F, Graham WV, Wang Y, et al. Interferon-gamma and tumor necrosis factor-alpha synergize to induce intestinal epithelial barrier dysfunction by up-regulating myosin light chain kinase expression. Am J Pathol. 2005;166:409–419.
   PubMed Web of Science ®Google Scholar
• Park JH, Rhee PL, Kim G, et al. Enteroendocrine cell counts correlate with visceral hypersensitivity in patients with diarrhoea-predominant irritable bowel syndrome. Neurogastroenterol Motil. 2006;18:539–546.
   PubMed Web of Science ®Google Scholar
• Ohman L, Lindmark AC, Isaksson S, et al. B-cell activation in patients with irritable bowel syndrome (IBS). Neurogastroenterol Motil. 2009;21(644–50):e27.
   Google Scholar
• Rajilić-Stojanović M, Jonkers DM, Salonen A, et al. Intestinal microbiota and diet in IBS: causes, consequences, or epiphenomena? Am J Gastroenterol. 2015;110:278–287.
   PubMed Web of Science ®Google Scholar
• Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364:22–32.
   PubMed Web of Science ®Google Scholar
• Chung CS, Chang PF, Liao CH, et al. Differences of microbiota in small bowel and faeces between irritable bowel syndrome patients and healthy subjects. Scand J Gastroenterol. 2016;51:410–419.
   PubMed Web of Science ®Google Scholar
• Ghoshal UC, Srivastava D. Irritable bowel syndrome and small intestinal bacterial overgrowth, meaningful association or unnecessary hype. World J Gastroenterol. 2014;20:2482–2491.
   PubMed Web of Science ®Google Scholar
• Długosz A, Winckler B, Lundin E, et al. No difference in small bowel microbiota between patients with irritable bowel syndrome and healthy controls. Sci Rep. 2015;5:8508.
   PubMed Web of Science ®Google Scholar
• Ghoshal UC, Srivastava D, Misra A, et al. A proof-of-concept study showing antibiotics to be more effective in irritable bowel syndrome with than without small-intestinal bacterial overgrowth: a randomized, double-blind, placebo-controlled trial. Eur J Gastroenterol Hepatol. 2016;28:281–289.
   PubMed Web of Science ®Google Scholar
• Weinberg DS, Smalley W, Heidelbaugh JJ, et al. American Gastroenterological Association Institute Guideline on the pharmacological management of irritable bowel syndrome. Gastroenterology. 2014;147:1146–1148.
   PubMed Web of Science ®Google Scholar
• Scarpignato C, Dolak W, Lanas A, et al. Rifaximin reduces the number and severity of intestinal lesions associated with use of nonsteroidal anti-inflammatory drugs in humans. Gastroenterology. 2017;152(980–982.e3).
   PubMed Web of Science ®Google Scholar
• Aziz I, Törnblom H, Simrén M. Small intestinal bacterial overgrowth as a cause for irritable bowel syndrome: guilty or not guilty? Curr Opin Gastroenterol. 2017;33:196–202.
   PubMed Web of Science ®Google Scholar
• Zeber-Lubecka N, Kulecka M, Ambrozkiewicz F, et al. Limited prolonged effects of rifaximin treatment on irritable bowel syndrome-related differences in the fecal microbiome and metabolome. Gut Microbes. 2016;7:397–413.
   PubMed Web of Science ®Google Scholar
• Ghoshal UC, Shukla R, Ghoshal U. Small intestinal bacterial overgrowth and irritable bowel syndrome: a bridge between functional organic dichotomy. Gut Liver. 2017;11:196–208.
   PubMed Web of Science ®Google Scholar
• Schoenfeld PS. Advances in IBS 2016: a review of current and emerging data. Gastroenterol Hepatol (N Y). 2016;12:1–11.
   PubMedGoogle Scholar
• Li J, Zhu W, Liu W, et al. Rifaximin for irritable bowel syndrome: a meta-analysis of randomized placebo-controlled trials. Medicine (Baltimore). 2016;95:e2534.
   PubMed Web of Science ®Google Scholar
• Halmos EP, Power VA, Shepherd SJ, et al. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology. 2014;146:67–75.e5.
   PubMed Web of Science ®Google Scholar
• Eswaran SL, Chey WD, Han-Markey T, et al. A randomized controlled trial comparing the low FODMAP diet vs. modified NICE guidelines in US adults with IBS-D. Am J Gastroenterol. 2016;111:1824–1832.
   PubMed Web of Science ®Google Scholar
• Bennet SMP, Böhn L, Störsrud S, et al. Multivariate modelling of faecal bacterial profiles of patients with IBS predicts responsiveness to a diet low in FODMAPs. Gut. 2017 Apr 17. pii: gutjnl-2016-313128. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Hill C, Guarner F, Reid G, et al. Expert consensus document: the International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11:506–514.
   PubMed Web of Science ®Google Scholar
• Food and Agriculture Organization/World Health Organization. Joint FAO/WHO working group report on drafting guidelines for the evaluation of probiotics in food. 2002. London, ON, Canada.
   Google Scholar
• Didari T, Mozaffari S, Nikfar S, et al. Effectiveness of probiotics in irritable bowel syndrome: updated systematic review with meta-analysis. World J Gastroenterol. 2015;21:3072–3084.
   PubMed Web of Science ®Google Scholar
• Moayyedi P, Ford AC, Talley NJ, et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut. 2010;59:325–332.
   PubMed Web of Science ®Google Scholar
• McFarland LV, Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol. 2008;14:2650–2661.
   PubMed Web of Science ®Google Scholar
• Hoveyda N, Heneghan C, Mahtani KR, et al. A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterol. 2009;9:15.
   PubMed Web of Science ®Google Scholar
• Ortiz-Lucas M, Tobías A, Saz P, et al. Effect of probiotic species on irritable bowel syndrome symptoms: a bring up to date meta-analysis. Rev Esp Enferm Dig. 2013;105:19–36.
   PubMed Web of Science ®Google Scholar
• Tiequn B, Guanqun C, Shuo Z. Therapeutic effects of Lactobacillus in treating irritable bowel syndrome: a meta-analysis. Intern Med. 2015;54:243–249.
   PubMed Web of Science ®Google Scholar
• Ford AC, Quigley EM, Lacy BE, et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol. 2014;109:1547–1561.
   PubMed Web of Science ®Google Scholar
• Dimidi E, Christodoulides S, Fragkos KC, et al. The effect of probiotics on functional constipation in adults: a systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr. 2014;100:1075–1084.
   PubMed Web of Science ®Google Scholar
• Chmielewska A, Szajewska H. Systematic review of randomised controlled trials: probiotics for functional constipation. World J Gastroenterol. 2010;16:69–75.
   PubMed Web of Science ®Google Scholar
• Layer P, Andresen V, Pehl C, et al. Irritable bowel syndrome: German consensus guidelines on definition, pathophysiology and management. Z Gastroenterol. 2011;49:237–293.
   PubMed Web of Science ®Google Scholar
• Ford AC, Moayyedi P, Lacy BE, et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol. 2014;109:S2–26.
   PubMed Web of Science ®Google Scholar
• Allen AP, Clarke G, Cryan JF, et al. Bifidobacterium infantis 35624 and other probiotics in the management of irritable bowel syndrome. Strain specificity, symptoms and mechanisms. Curr Med Res Opin. 2017;22:1–8.
   Google Scholar
• Pa B, Kleerebezem M, R-J B, et al. Can probiotics modulate human disease by impacting intestinal barrier function? Br J Nutr. 2017;117:93–107.
   PubMed Web of Science ®Google Scholar
• Cleusix V, Lacroix C, Vollenweider S, et al. Inhibitory activity spectrum of reuterin produced by Lactobacillus reuteri against intestinal bacteria. BMC Microbiol. 2007;7:101.
   PubMed Web of Science ®Google Scholar
• Corr SC, Li Y, Riedel CU, et al. Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118. Proc Natl Acad Sci U S A. 2007;104:7617–7621.
   PubMed Web of Science ®Google Scholar
• Klaenhammer TR, Kleerebezem M, Kopp MV, et al. The impact of probiotics and prebiotics on the immune system. Nat Rev Immunol. 2012;12:728–734.
   PubMed Web of Science ®Google Scholar
• Glenting J, Beck HC, Vrang A, et al. Anchorless surface associated glycolytic enzymes from Lactobacillus plantarum 299v bind to epithelial cells and extracellular matrix proteins. Microbiol Res. 2013;168:245–253.
   PubMed Web of Science ®Google Scholar
• Mangell P, Lennernas P, Wang M, et al. Adhesive capability of Lactobacillus plantarum 299v is important for preventing bacterial translocation in endotoxemic rats. Apmis. 2006;114:611–618.
   PubMed Web of Science ®Google Scholar
• Lottenberg R, DesJardin LE, Wang H, et al. Streptokinase-producing streptococci grown in human plasma acquire unregulated cell-associated plasmin activity. J Infect Dis. 1992;166:436–440.
   PubMed Web of Science ®Google Scholar
• Modun B, Williams P. The staphylococcal transferrin-binding protein is a cell wall glyceraldehyde-3-phosphate dehydrogenase. Infect Immun. 1999;167:1086–1092.
   Google Scholar
• Goudot-Crozel V, Caillol D, Djabali M, et al. The major parasite surface antigen associated with human resistance to schistosomiasis is a 37-kD glyceraldehyde-3P-dehydrogenase. J Exp Med. 1989;170:2065–2080.
   PubMed Web of Science ®Google Scholar
• Pancholi V, Fischetti VA. A major surface protein on group A streptococci is a glyceraldehyde-3-phosphate-dehydrogenase with multiple binding activity. J Exp Med. 1992;176:415–426.
   PubMed Web of Science ®Google Scholar
• Whiting GC, Evans JT, Patel S, et al. Purification of native alpha-enolase from Streptococcus pneumoniae that binds plasminogen and is immunogenic. J Med Microbiol. 2002;51:837–843.
   PubMed Web of Science ®Google Scholar
• Molkanen T, Tyynela J, Helin J, et al. Enhanced activation of bound plasminogen on Staphylococcus aureus by staphylokinase. FEBS Lett. 2002;517:72–78.
   PubMed Web of Science ®Google Scholar
• Jong AY, Chen SH, Stins MF, et al. Binding of Candida albicans enolase to plasmin(ogen) results in enhanced invasion of human brain microvascular endothelial cells. J Med Microbiol. 2003;52:615–622.
   PubMed Web of Science ®Google Scholar
• Mack DR, Michail S, Wei S, et al. Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression. Am J Physiol. 1999;276:G941–50.
   PubMed Web of Science ®Google Scholar
• Mack DR, Ahrne S, Hyde L, et al. Extracellular MUC3 mucin secretion follows adherence of Lactobacillus strains to intestinal epithelial cells in vitro. Gut. 2003;52:827–833.
   PubMed Web of Science ®Google Scholar
• Wallace JL, Miller MJ. Nitric oxide in mucosal defense: a little goes a long way. Gastroenterology. 2000;119:512–520.
   PubMed Web of Science ®Google Scholar
• Loonen LMP, Stolte EH, Jaklofsky MTJ, et al. REG3y-deficient mice have altered mucus distribution and increased mucosal inflammatory responses to the microbiota and enteric pathogens in the ileum. Mucosal Immunol. 2014;7:939–947.
   PubMed Web of Science ®Google Scholar
• Altenhoefer A, Oswald S, Sonnenborn U, et al. The probiotic Escherichia coli strain Nissle 1917 interferes with invasion of human intestinal epithelial cells by different enteroinvasive bacterial pathogens. FEMS Immunol Med Microbiol. 2004;40:223–229.
   PubMedGoogle Scholar
• Asahara T, Shimizu K, Nomoto K, et al. Probiotic bifidobacteria protect mice from lethal infection with Shiga toxin-producing Escherichia coli O157: H7. Infect Immun. 2004;72:2240–2247.
   PubMed Web of Science ®Google Scholar
• Castagliuolo I, LaMont JT, Nikulasson ST, et al. Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum. Infect Immun. 1996;64:5225–5232.
   PubMed Web of Science ®Google Scholar
• van Hemert S, Ormel G. Influence of the multispecies probiotic Ecologic® BARRIER on parameters of intestinal barrier function. FNS. 2014;5:1739–1745.
   Google Scholar
• Everard A, Geurts L, Caesar R, et al. Intestinal epithelial MyD88 is a sensor switching host metabolism towards obesity according to nutritional status. Nat Commun. 2014;5:5648.
   PubMed Web of Science ®Google Scholar
• Cash HL, Whitham CV, Behrendt CL, et al. Symbiotic bacteria direct expression of an intestinal bactericidal lectin. Science. 2006;313:1126–1130.
   PubMed Web of Science ®Google Scholar
• Brown EM, Sadarangani M, Finlay BB. The role of the immune system in governing host-microbe interactions in the intestine. Nat Immunol. 2013;14:660–667.
   PubMed Web of Science ®Google Scholar
• Verdù EF, Bercik P, Cukrowska B, et al. Oral administration of antigens from intestinal flora anaerobic bacteria reduces the severity of experimental acute colitis in BALB/c mice. Clin Exp Immunol. 2000;120:46–50.
   PubMed Web of Science ®Google Scholar
• Gross G, van der Meulen J, Snel J, et al. Mannose-specific interaction of Lactobacillus plantarum with porcine jejunal epithelium. FEMS Immunol Med Microbiol. 2008;54:215–223.
   PubMedGoogle Scholar
• Zakostelska Z, Kverka M, Klimesova K, et al. Lysate of probiotic Lactobacillus casei DN-114 001 ameliorates colitis by strengthening the gut barrier function and changing the gut microenvironment. Plos One. 2011;6:e27961.
   PubMed Web of Science ®Google Scholar
• Smits LP, Bouter KE, de Vos WM, et al. Therapeutic potential of fecal microbiota transplantation. Gastroenterology. 2013;145:946–953.
   PubMed Web of Science ®Google Scholar
• Borody TJ, Connelly N, Mitchell SW. Fecal microbiota transplantation in gastrointestinal diseases: what practicing physicians should know. Pol Arch Med Wewn. 2015;125:852–858.
   PubMed Web of Science ®Google Scholar
• Hamilton MJ, Weingarden AR, Sadowsky MJ, et al. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am J Gastroenterol. 2012;107:761–767.
   PubMed Web of Science ®Google Scholar
• Cammarota G, Ianiro G, Tilg H, et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut. 2017;66:569–580.
   PubMed Web of Science ®Google Scholar
• König J, Siebenhaar A, Högenauer C, et al. Consensus report: faecal microbiota transfer - clinical applications and procedures. Aliment Pharmacol Ther. 2017;45:222–239.
   PubMed Web of Science ®Google Scholar
• Borody T, Fischer M, Mitchell S, et al. Fecal microbiota transplantation in gastrointestinal disease: 2015 update and the road ahead. Expert Rev Gastroenterol Hepatol. 2015;9:1379–1391.
   PubMed Web of Science ®Google Scholar
• Konturek PC, Haziri D, Brzozowski T, et al. Emerging role of fecal microbiota therapy in the treatment of gastrointestinal and extra-gastrointestinal diseases. J Physiol Pharmacol. 2015;66(4):483–491.
   PubMed Web of Science ®Google Scholar
• Paramsothy S, Kamm MA, Kaakoush NO, et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet. 2017;389:1218–1228.
   PubMed Web of Science ®Google Scholar
• Marlicz W, Koulaouzidis A, Loniewski I, et al. Letter by Marlicz et al regarding article, “Proton pump inhibitors accelerate endothelial senescence”. Circ Res. 2016;119:e31–2.
   PubMed Web of Science ®Google Scholar
• Lo WK, Chan WW. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. Clin Gastroenterol Hepatol. 2013;11:483–490.
   PubMed Web of Science ®Google Scholar
• Wallace JL, Syer S, Denou E, et al. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology. 2011;141:1314-22,1322.e1-5.
   Web of Science ®Google Scholar
• Janarthanan S, Ditah I, Adler DG, et al. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol. 2012;107:1001–1010.
   PubMed Web of Science ®Google Scholar
• Spanogiannopoulos P, Bess EN, Carmody RN, et al. The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism. Nat Rev Microbiol. 2016;14:273–287.
   PubMed Web of Science ®Google Scholar
• Nayak RR, Turnbaugh PJ. Mirror, mirror on the wall, which microbiomes will help heal them all? BMC Med. 2016;14:72.
   PubMed Web of Science ®Google Scholar
• Anderson RC, Dalziel JE, Gopal PK, et al. The role of intestinal barrier function in early life in the development of colitis. In: Fukata M, editor. Colitis. InTech; 2012. Available from: https://www.intechopen.com/books/colitis/the-role-of-intestinal-barrier-function-in-early-life-in-the-development-of-colitis
   Google Scholar
• Martin R, Makino H, Cetinyurek Yavuz A, et al. Early-life events, including mode of delivery and type of feeding, siblings and gender, shape the developing gut microbiota. Plos One. 2016;11:e0158498.
   PubMed Web of Science ®Google Scholar
• Sood R, Ford AC. Diagnosis, Rome IV criteria for FGIDs - an improvement or more of the same? Nat Rev Gastroenterol Hepatol. 2016;13:501–502.
   PubMed Web of Science ®Google Scholar
• Noble EE, Hsu TM, Kanoski SE. Gut to brain dysbiosis, mechanisms linking western diet consumption, the microbiome, and cognitive impairment. Front Behav Neurosci. 2017;11:9.
   PubMed Web of Science ®Google Scholar
• Potgieter M, Bester J, Kell DB, et al. The dormant blood microbiome in chronic, inflammatory diseases. FEMS Microbiol Rev. 2015;39:567–591.
   PubMed Web of Science ®Google Scholar
• Fritscher-Ravens A, Schuppan D, Ellrichmann M, et al. Confocal endomicroscopy shows food-associated changes in the intestinal mucosa of patients with irritable bowel syndrome. Gastroenterology. 2014;147:1012–20.e4.
   PubMed Web of Science ®Google Scholar
• Delaney SK, Hultner ML, Jacob HJ, et al. Toward clinical genomics in everyday medicine: perspectives and recommendations. Expert Rev Mol Diagn. 2016;16:521–532.
   PubMed Web of Science ®Google Scholar
• https://genieur.eu/Last accessed 2017 June 14
   Google Scholar
• Johnson LC, Melmed GY, Nelson EC, et al. Fostering collaboration through creation of an IBD learning health system. Am J Gastroenterol. 2017 Mar;112(3):406–408.
   PubMed Web of Science ®Google Scholar